ZoomInfo Outlines Ambitious 2025 Financial Goals Amid Strategic Shift

Published 5 hours agoZI

ZoomInfo Outlines Ambitious 2025 Financial Goals Amid Strategic Shift

ZoomInfo Technologies Inc. has revealed its financial projections for 2025, signaling a shift towards capturing higher-value markets. The company forecasts a full-year GAAP revenue ranging from $1.185 billion to $1.205 billion, suggesting a slight dip from the previous year, as reported by Nasdaq. In line with its strategic adjustments, ZoomInfo aims for adjusted operating income to be between $426 million and $436 million, maintaining a healthy 36% margin.

ZoomInfo is particularly focusing on expanding its presence in the upmarket segment, significantly leveraging its Copilot product, which has surpassed $150 million in Annual Contract Value (ACV), according to GuruFocus. However, challenges remain in the down-market sector, which shrank by 9% in 2024 and is expected to face further declines in 2025. Additionally, the company announced an extra $500 million share repurchase program, following the buyback of 46 million shares last year, as noted by Invezz.

In its strategy for 2025, ZoomInfo is determined to bolster upmarket growth and capital allocation. These include prioritizing new initiatives and continuing share repurchases to maximize shareholder value. Despite facing challenges in certain segments, the company remains committed to strengthening its market position and broadening its innovative offerings.

Share this article

Twitter Facebook LinkedIn

Recent Articles

China Lifts Boeing Ban Amid US-China Trade Truce

China Lifts Boeing Ban Amid US-China Trade Truce

59 minutes agoBA

In a notable development, China has lifted its long-standing ban on Boeing plane deliveries, including the 737 MAX and 787 Dreamliner models. This marks the end of nearly five years of delivery suspensions and coincides with new progress in US-China trade talks. The US and China have reached a pivotal agreement to reduce tariffs, aiming to ease trade tensions with a 90-day truce. Reuters reported that the US slashed its tariffs on Chinese goods from 145% to 30%, while China cut its tariffs on US goods to 10%. This mutual decision has generated optimism within markets, notably boosting sectors such as apparel, footwear, and travel, which are heavily dependent on the two countries' trade relations. Boeing has strategically emphasized its commitment to the lucrative Chinese market. Boeing's China President, Alvin Liu, highlighted the exciting possibilities for collaborative efforts in the field of low-altitude logistics. Following these developments, Boeing's stock responded positively, trading at $198.53, marking an increase of $3.63 or 1.86%. The company appears set to strengthen its presence in the Chinese market amidst an improving bilateral trade environment.

Sangamo Therapeutics Reports Narrower Losses and Strategic Gains in 2024

Sangamo Therapeutics Reports Narrower Losses and Strategic Gains in 2024

1 hours agoSGMO

Sangamo Therapeutics recently announced its financial results for the fourth quarter and full year of 2024, showing improvement in its loss figures. The company reported a net loss of $23.4 million, or $0.11 per share, for the fourth quarter of 2024, compared to a $60.3 million loss, or $0.34 per share, in the same period in 2023. For the full year, Sangamo saw a net loss of $97.9 million, or $0.49 per share, significantly better than the $257.8 million loss, or $1.48 per share, recorded in 2023. Revenue for the fourth quarter was $7.6 million, falling short of the $10.32 million predicted by analysts. The company has made strides in its strategic development goals, having entered into two major neurology license agreements in 2024. In August, Sangamo signed an agreement with Genentech for the global use of epigenetic regulation and capsid delivery for neurodegenerative diseases. Later, in December, the company inked another deal with Astellas for capsid licensing, targeting up to five neurological disease areas. Additionally, the FDA approved Sangamo's IND application for its new pain treatment candidate, ST-503, paving the way for patient enrollment by mid-2025. Looking ahead, Sangamo is focusing its strategic efforts on strengthening its neurology pipeline and advance its treatment for Fabry disease, isaralgagene civaparvovec, towards potential Accelerated Approval with the FDA. In clinical updates, the Phase 1/2 STAAR study for this treatment reported ongoing benefits and improved kidney function. Despite revenue setbacks, Sangamo's positive regulatory and strategic developments underscore its commitment to expanding treatment options for critical neurological and genetic conditions.

Telefonica Brasil's Earnings Surge Far Exceeding Expectations

Telefonica Brasil's Earnings Surge Far Exceeding Expectations

Telefonica Brasil has reported a remarkable financial performance, as evidenced by its most recent earnings release. The company posted an earnings per share (EPS) of $1.08, significantly outperforming analyst expectations, which stood at just $0.174. Additionally, Telefonica Brasil's revenue came in at an impressive $14.58 billion, far exceeding the consensus estimate of $2.48 billion, as reported by investing.com. Supporting these robust results, Telefonica Brasil's net income rose to 1.76 billion reais ($306.64 million), marking a year-over-year increase of 10.1%, as noted by marketscreener.com. The company's mobile services revenue grew by 7.0% to 9.2 billion reais, while its fixed revenue saw an 8.0% uptick, driven by Fiber-to-the-Home (FTTH), and Corporate Data, ICT, and Digital Services. The company's EBITDA also experienced a healthy growth of 7.8%, reaching 6.2 billion reais with a margin of 42.5%. Meanwhile, capital expenditure rose 2.3% from the previous year, totaling 9.166 billion reais. Telefonica Brasil's focus on shareholder remuneration was evident, distributing 5.845 billion reais, which represents a 22.1% increase from the previous year, equating to a payout of 105.3% of net income. These figures reflect the company's strategic focus on maintaining financial stability while enhancing shareholder value.

OncoCyte Expands Transplant Diagnostics with Key Partnerships

OncoCyte Expands Transplant Diagnostics with Key Partnerships

OncoCyte Corporation is advancing its presence in the transplant diagnostics market through significant new agreements. The company has recently secured partnerships with top transplant centers in both the United States and Germany. These centers will use OncoCyte's GraftAssure™ assay, a specialized test designed to detect early signs of organ graft damage, according to a report by GlobeNewswire. Supporting its diagnostics expansion, OncoCyte is making headway in FDA-related activities. The company is progressing with the development of a kitted clinical test product, having held a pre-submission meeting with the U.S. Food and Drug Administration on December 5, 2024. OncoCyte plans to submit this clinical test for FDA approval by the end of 2025, with hopes for authorization by 2026, as detailed by NatLawReview. In a strategic move to align with future industry standards, OncoCyte is also embarking on a rebranding initiative. This shift is in anticipation of a broader transition in transplant care, where localized, real-time monitoring is expected to become standard practice by 2028. The company's efforts reflect its commitment to accessible and efficient transplant diagnostics, aiming to innovate and lead in this evolving field.